메디시노바 (MNOV) 주가

메디시노바(MNOV)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.31 (+0.00%), 시가총액 $0.07B, 52주 범위 $1.18 ~ $1.88.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical tri

핵심 지표

• 현재가: $1.31 (+0.00%)
• 시가총액: $0.07B
• 52주 최저~최고: $1.18 ~ $1.88
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

메디시노바의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

메디시노바 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.74
• 순이익률: 0.00%
• 영업이익률: -15.17%

자주 묻는 질문